UBS Asset Management Americas Inc. Has $661,000 Position in Blueprint Medicines Corporation (BPMC)

UBS Asset Management Americas Inc. boosted its holdings in Blueprint Medicines Corporation (NASDAQ:BPMC) by 160.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 13,051 shares of the biotechnology company’s stock after acquiring an additional 8,036 shares during the period. UBS Asset Management Americas Inc.’s holdings in Blueprint Medicines Corporation were worth $661,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. SG Americas Securities LLC grew its stake in Blueprint Medicines Corporation by 23.3% in the 2nd quarter. SG Americas Securities LLC now owns 4,113 shares of the biotechnology company’s stock valued at $208,000 after acquiring an additional 778 shares during the last quarter. Prudential Financial Inc. boosted its stake in shares of Blueprint Medicines Corporation by 6.0% during the 1st quarter. Prudential Financial Inc. now owns 17,304 shares of the biotechnology company’s stock worth $692,000 after purchasing an additional 984 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Blueprint Medicines Corporation by 31.8% during the 1st quarter. Legal & General Group Plc now owns 5,884 shares of the biotechnology company’s stock worth $235,000 after purchasing an additional 1,419 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Blueprint Medicines Corporation by 10.2% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 17,155 shares of the biotechnology company’s stock worth $686,000 after purchasing an additional 1,589 shares during the last quarter. Finally, Fiduciary Trust Co. boosted its stake in shares of Blueprint Medicines Corporation by 21.5% during the 2nd quarter. Fiduciary Trust Co. now owns 12,468 shares of the biotechnology company’s stock worth $632,000 after purchasing an additional 2,203 shares during the last quarter. 90.79% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/11/blueprint-medicines-corporation-bpmc-shares-bought-by-ubs-asset-management-americas-inc.html.

Shares of Blueprint Medicines Corporation (NASDAQ BPMC) traded down $1.90 on Friday, hitting $68.32. 265,800 shares of the stock traded hands, compared to its average volume of 431,462. Blueprint Medicines Corporation has a 52 week low of $25.08 and a 52 week high of $74.42. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28.

Blueprint Medicines Corporation (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.06). Blueprint Medicines Corporation had a negative net margin of 437.83% and a negative return on equity of 43.11%. The company had revenue of $8.07 million for the quarter, compared to the consensus estimate of $5.35 million. During the same quarter in the prior year, the firm earned ($0.62) earnings per share. Blueprint Medicines Corporation’s revenue for the quarter was up 31.0% compared to the same quarter last year. analysts anticipate that Blueprint Medicines Corporation will post -3.74 earnings per share for the current year.

Several equities research analysts recently issued reports on BPMC shares. Zacks Investment Research raised shares of Blueprint Medicines Corporation from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Canaccord Genuity set a $56.00 price target on shares of Blueprint Medicines Corporation and gave the company a “buy” rating in a report on Wednesday, August 2nd. BidaskClub lowered shares of Blueprint Medicines Corporation from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 19th. Wedbush restated an “outperform” rating and issued a $66.00 price target on shares of Blueprint Medicines Corporation in a report on Tuesday, August 22nd. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $56.00 price objective on shares of Blueprint Medicines Corporation in a research note on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $70.47.

In other Blueprint Medicines Corporation news, Director Daniel Lynch sold 2,500 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the sale, the director now owns 209,342 shares in the company, valued at approximately $12,560,520. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jeffrey W. Albers sold 30,000 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $70.31, for a total value of $2,109,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 49,305 shares of company stock worth $3,354,882. Company insiders own 3.40% of the company’s stock.

Blueprint Medicines Corporation Profile

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Institutional Ownership by Quarter for Blueprint Medicines Corporation (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply